유전자 융합 검사 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 카테고리별, 기술별, 적응증별, 최종사용자별, 지역별, 경쟁별(2020-2030F)
Gene Fusion Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Category, By Technology, By Indication, By End User, By Region and Competition, 2020-2030F
상품코드:1703265
리서치사:TechSci Research
발행일:2025년 04월
페이지 정보:영문 182 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 유전자 융합 검사 시장은 2024년에 4억 7,124만 달러로 평가되고, 예측 기간에는 9억 4,749만 달러에 달할 것으로 예측되며, 2030년까지 CAGR은 12.32%입니다.
유전자 융합은 유전자 전좌 또는 염색체 전좌라고도 하며, 유전체의 서로 다른 영역에 있는 두 개의 서로 다른 유전자가 비정상적으로 결합하거나 융합하여 발생하는 유전적 사건입니다. 이 융합은 키메라 유전자라고도 하는 두 유전자의 일부가 결합된 하이브리드 유전자의 생성을 초래할 수 있습니다. 유전자 융합 현상은 특히 인간 세포에서 발생하며, 암과 같은 질병과 관련이 있는 경우 생물의 건강에 심각한 영향을 미칠 수 있습니다. 유전자 융합은 종종 염색체 전좌라는 과정을 통해 유전 물질의 재배열이 일어날 때 발생합니다. 염색체 전좌는 한 염색체의 일부가 절단되어 다른 염색체에 결합하여 이들 염색체 상에 위치한 유전자의 융합으로 이어집니다.
시장 개요
예측 기간
2026-2030
시장 규모 : 2024년
4억 7,124만 달러
시장 규모 : 2030년
9억 4,749만 달러
CAGR : 2025-2030년
12.32%
급성장 부문
제약·바이오테크놀러지 기업
최대 시장
북미
특정 유전자 융합 사건을 식별하는 것은 특히 암에서 진단 및 치료와 밀접한 관련이 있습니다. 유전자 융합 검사는 이러한 사건을 감지하고 치료 방침을 결정하는 데 사용됩니다. 경우에 따라 비정상적인 키메라 단백질의 기능을 억제하는 표적치료제가 개발되고 있습니다. 암 치료를 위한 표적 치료의 개발과 채택은 유전자 융합의 검출을 포함한 종양의 정밀한 분자 프로파일링의 필요성을 촉진하고 있습니다. 이러한 치료법은 종종 치료 표적으로서 특정 유전자 변이를 식별하는 데 의존합니다. 유전체 기술, 특히 차세대 염기서열 분석(NGS)과 고처리량 분자 분석의 지속적인 발전은 유전자 융합 검사를 보다 접근하기 쉽고, 비용 효율적이며, 효율적으로 만들었습니다. 연구 노력은 암을 포함한 다양한 질병에서 새로운 유전자 융합 사건과 그 연관성을 지속적으로 밝혀내고 있습니다. 이러한 연구는 유전자 융합 검사의 개발 및 상용화에 대한 관심을 불러일으켰습니다.
주요 시장 성장 촉진요인
게놈 기술의 진보
주요 시장이 해결해야 할 과제
조직의 가용성
주요 시장 동향
맞춤형 의료
목차
제1장 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 세계의 유전자 융합 검사 시장 전망
시장 규모·예측
금액별
시장 점유율·예측
카테고리별(조사, 진단)
기술별(차세대 시퀀싱(NGS), 형광 in-situ 하이브리다이제이션(FISH), 중합효소 연쇄 반응(PCR), 면역조직화학(IHC))
적응증별(고형 종양, 조혈 악성 종양)
최종사용자별(제약·바이오테크놀러지 기업, 병원·진단 연구소, 학술연구 센터)
지역별
기업별(2024)
시장 맵
제6장 아시아태평양의 유전자 융합 검사 시장 전망
시장 규모·예측
시장 점유율·예측
아시아태평양 : 국가별 분석
중국
인도
호주
일본
한국
제7장 유럽의 유전자 융합 검사 시장 전망
시장 규모·예측
시장 점유율·예측
유럽 : 국가별 분석
프랑스
독일
스페인
이탈리아
영국
제8장 북미의 유전자 융합 검사 시장 전망
시장 규모·예측
시장 점유율·예측
북미 : 국가별 분석
미국
멕시코
캐나다
제9장 남미의 유전자 융합 검사 시장 전망
시장 규모·예측
시장 점유율·예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 유전자 융합 검사 시장 전망
시장 규모·예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트
제11장 시장 역학
촉진요인
과제
제12장 시장 동향과 발전
최근 동향
제품 출시
합병과 인수
제13장 세계의 유전자 융합 검사 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 PESTEL 분석
제16장 경쟁 구도
Amoy Diagnostics Co., Ltd.
ArcherDX(Integrated DNA Technologies, Inc.)
Biocartis
Biocare Medical, LLC
F. Hoffmann-La Roche Ltd.
Guardant Health, Inc
Illumina, Inc.
Myriad Genetics, Inc.
Natera, Inc.
NeoGenomics, Inc.
QIAGEN N.V.
Thermo Fisher Scientific Inc
제17장 전략적 제안
제18장 조사회사 소개·면책사항
KSA
영문 목차
영문목차
Global Gene Fusion Testing Market was valued at USD 471.24 Million in 2024 and is expected to reach USD 947.49 Million in the forecast period with a CAGR of 12.32% through 2030. Gene fusion, also known as gene translocation or chromosomal translocation, is a genetic event that occurs when two separate genes from different regions of the genome become abnormally connected or fused together. This fusion can result in the creation of a hybrid gene, also known as a chimeric gene, which combines portions of both original genes. Gene fusion events can have significant implications for an organism's health, particularly when they occur in human cells and are associated with diseases, such as cancer. Gene fusion occurs when there is a rearrangement of genetic material, often through a process called chromosomal translocation. In chromosomal translocation, a piece of one chromosome breaks off and attaches to another chromosome, leading to the fusion of genes located on these chromosomes.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 471.24 Million
Market Size 2030
USD 947.49 Million
CAGR 2025-2030
12.32%
Fastest Growing Segment
Pharmaceutical and Biotechnology Companies
Largest Market
North America
Identifying specific gene fusion events is of great diagnostic and therapeutic relevance, particularly in cancer. Gene fusion testing is used to detect these events and guide treatment decisions. In some cases, targeted therapies have been developed to inhibit the function of abnormal chimeric proteins. The development and adoption of targeted therapies for cancer treatment were driving the need for precise molecular profiling of tumors, including the detection of gene fusions. These therapies often rely on the identification of specific genetic alterations as therapeutic targets. Ongoing advancements in genomic technologies, particularly next-generation sequencing (NGS) and high-throughput molecular assays, were making gene fusion testing more accessible, cost-effective, and efficient. Research efforts were continually uncovering new gene fusion events and their relevance in various diseases, including cancer. This research drove interest in developing and commercializing gene fusion tests.
Key Market Drivers
Advancements in Genomic Technologies
Next-Generation Sequencing (NGS) technologies, such as Illumina and Ion Torrent, have revolutionized genomics research and clinical diagnostics by enabling rapid and cost-effective sequencing of DNA and RNA.
Long-read sequencing technologies, such as those developed by Pacific Biosciences (PacBio) and Oxford Nanopore, provide a more comprehensive view of the genome, particularly useful for detecting structural variants and complex genomic regions. The CRISPR-Cas9 system has transformed genome editing, enabling precise and targeted gene modifications, making it a powerful tool for functional genomics, gene therapy, and genetic engineering. Notably, in December 2023, the U.S. Food and Drug Administration approved Casgevy, the first CRISPR-based treatment for sickle cell disease and beta-thalassemia, marking a significant milestone in gene-editing therapeutics.
Advances in technologies like DNA methylation sequencing (bisulfite sequencing) and chromatin immunoprecipitation sequencing (ChIP-seq) have deepened our understanding of epigenetic modifications and their roles in gene regulation and disease. Techniques such as single-molecule fluorescence in situ hybridization (smFISH) and single-molecule real-time (SMRT) sequencing offer insights into molecular processes at the individual molecule level. Metagenomic sequencing facilitates the study of microbial communities and their genetic diversity, with applications in environmental microbiology, microbiome research, and infectious disease diagnostics.
Key Market Challenges
Tissue Availability
In some cases, obtaining enough tissue for gene fusion testing can be challenging, especially when dealing with small biopsies or fine-needle aspirates. Insufficient tissue can result in inadequate test results. The quality of tissue samples is crucial for accurate gene fusion testing. Factors such as tissue preservation, fixation, and handling can impact the integrity of the genetic material and affect the reliability of test results. Tumors are often heterogeneous, meaning that different regions of the tumor may have distinct genetic profiles, including gene fusion events. Obtaining a single tissue sample may not fully represent the genetic diversity within the tumor. In some cases, tumors may be in anatomically challenging or inaccessible areas, making it difficult to obtain tissue samples for testing. Invasive procedures like biopsies carry inherent risks, including bleeding, infection, and damage to surrounding tissues. These risks can influence the decision to perform a biopsy and impact tissue availability. For rare or uncommon tumor types, obtaining sufficient tissue samples for gene fusion testing can be particularly challenging due to the limited number of cases available for study. Properly preserving and storing tissue samples for future testing is essential. Inadequate preservation or long-term storage conditions can compromise the quality of the samples. Obtaining informed consent for tissue collection is crucial, and ethical considerations may affect the availability of tissue samples, especially in cases involving minors or vulnerable populations.
Key Market Trends
Personalized Medicine
Gene fusion testing plays a crucial role in identifying specific genetic alterations that drive diseases, particularly in cancer. With the advent of personalized medicine, oncologists and other healthcare providers can use the results of gene fusion tests to select targeted therapies that are most likely to be effective for individual patients. This approach maximizes treatment efficacy while minimizing side effects. Gene fusion testing is used to stratify patients into different subgroups based on their genetic profiles. Patients with similar gene fusion events may respond differently to treatments. Personalized medicine enables the selection of the most appropriate treatment regimen for each patient based on their specific genetic alterations. Gene fusion tests are often developed alongside targeted therapies as companion diagnostics. These tests help identify patients who are most likely to benefit from a particular drug. Regulatory agencies like the U.S. Food and Drug Administration (FDA) often require companion diagnostics as part of the drug approval process. Personalized medicine extends beyond initial treatment selection. It also involves ongoing monitoring of a patient's response to therapy. Gene fusion testing can be used to assess whether a targeted therapy is effectively suppressing the fusion event and whether treatment adjustments are needed.
Key Market Players
Amoy Diagnostics Co., Ltd.
ArcherDX (Integrated DNA Technologies, Inc.)
Biocartis
Biocare Medical, LLC
F. Hoffmann-La Roche Ltd.
Guardant Health, Inc
Illumina, Inc.
Myriad Genetics, Inc.
Natera, Inc.
NeoGenomics, Inc.
QIAGEN N.V.
Thermo Fisher Scientific Inc
Report Scope:
In this report, the Global Gene Fusion Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Gene Fusion Testing Market, By Category:
Research
Diagnostic
Gene Fusion Testing Market, By Technology:
Next-Generation Sequencing (NGS)
Fluorescence In-Situ Hybridization (FISH)
Polymerase Chain Reaction (PCR)
Immunohistochemistry (IHC)
Gene Fusion Testing Market, By Indication:
Solid Tumors
Hematological Malignancies
Gene Fusion Testing Market, By End User:
Pharmaceutical and Biotechnology Companies
Hospitals and Diagnostic Laboratories
Academic and Research Centers
Global Gene Fusion Testing Market, By region:
North America
United States
Canada
Mexico
Asia-Pacific
China
India
South Korea
Australia
Japan
Europe
Germany
France
United Kingdom
Spain
Italy
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Gene Fusion Testing Market.
Available Customizations:
Global Gene Fusion Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
